Emerging paradigms mandate discovery of imaging agents for diagnosing Alzheimer's disease (AD) prior to appearance of clinical symptoms. To accomplish this objective, a novel heterocyclic molecule (4) was synthesized and validated as Aβ targeted probe. The agent shows labeling of numerous diffuse Aβ plaques in confirmed AD human brain tissues and traverses the blood-brain barrier to enable labeling of parenchymal Aβ plaques in live mice (APP ±/PS1±) brains.

Original languageEnglish
Pages (from-to)3640-3643
Number of pages4
JournalOrganic Letters
Issue number14
StatePublished - Jul 18 2014


Dive into the research topics of 'Characterization of a brain permeant fluorescent molecule and visualization of Aβ parenchymal plaques, using real-time multiphoton imaging in transgenic mice'. Together they form a unique fingerprint.

Cite this